Summary: In primary prevention patients at intermediate risk of cardiovascular disease (ie, at risk but without known disease), avoiding the addition of candesartan + hydrochlorothiazide appears to be associated with the same risk of cardiovascular death, non-fatal MI, or nonfatal stroke, but lower rates of hypotension, dizziness, or lightheadedness. (In otherwords, for a patients at intermediate risk of cardiovascular disease, treatment with candesartan + hydrochlorothiazide is not associated with any cardiovascular benefit over 5 years but may lead to more hypotension, dizziness, or lightheadedness)

NOTE: The average blood pressure of patients at enrollment in this study was ~ 138/82.

Strength of Recommendation = B